N-SMase2 Inhibitors
N-SMase2, also known as neutral sphingomyelinase 2, is an enzyme involved in sphingomyelin metabolism and cellular signaling pathways. Its primary function is the hydrolysis of sphingomyelin, a membrane lipid, into ceramide and phosphocholine. This enzymatic reaction plays a crucial role in regulating cell membrane structure and function, as well as participating in various cellular processes such as apoptosis, inflammation, and stress responses. N-SMase2 is predominantly localized in the Golgi apparatus and endosomal compartments, where it acts on sphingomyelin-containing membranes to generate ceramide, a bioactive lipid involved in signaling cascades.
Inhibition of N-SMase2 activity can occur through various mechanisms, disrupting the enzyme's function and downstream signaling pathways. One common mechanism of inhibition involves the direct binding of inhibitors to the active site of N-SMase2, hindering its interaction with sphingomyelin substrates. Additionally, inhibition may occur through modulation of upstream signaling pathways that regulate N-SMase2 activity, such as receptor-mediated signaling or intracellular calcium levels. Another mechanism of inhibition involves interference with N-SMase2 localization or post-translational modifications essential for its enzymatic activity. By inhibiting N-SMase2, the production of ceramide is reduced, leading to alterations in cellular signaling and physiological responses. Consequently, inhibition of N-SMase2 may have implications in diseases associated with dysregulated sphingolipid metabolism, such as neurodegenerative disorders, cancer, and inflammatory conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is crucial for cell survival and growth. Inhibition of PI3K by LY294002 can disrupt downstream signaling, potentially affecting NSMA2-related processes by altering cellular growth signals, which might indirectly influence NSMA2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is part of the MAPK/ERK pathway. This pathway is involved in cell proliferation and differentiation. Inhibition of MEK by PD98059 could affect the signaling cascade, potentially impacting NSMA2's role in gene expression regulation by modifying transcriptional activities. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 selectively inhibits the TGF-β receptor, a key component of the TGF-β signaling pathway. This pathway influences cell differentiation and proliferation. By inhibiting this receptor, SB431542 may indirectly affect NSMA2 activity by altering the cellular environment and response to growth factors. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, impacting the PI3K/AKT/mTOR pathway. mTOR is a central regulator of cell growth and proliferation. By inhibiting mTOR, Rapamycin could affect NSMA2's activity indirectly through alterations in cellular growth and survival signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathway. JNK is involved in controlling gene expression and apoptosis. Inhibition of JNK by SP600125 might indirectly modulate NSMA2 activity by affecting stress response pathways and gene expression profiles. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, affecting the PI3K/AKT/mTOR pathway. By inhibiting PI3K, Wortmannin can disrupt cellular signaling involved in growth and survival, potentially influencing NSMA2 by altering the cellular environment and gene expression patterns. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, also known as AZD6244, is a selective MEK1/2 inhibitor. It targets the MAPK/ERK pathway, influencing cell proliferation and survival. Inhibiting MEK1/2 with Selumetinib could indirectly affect NSMA2 activity by modulating the cellular signaling involved in growth and differentiation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor, primarily targeting BCR-ABL and SRC family kinases. Its inhibition of multiple kinases can affect various signaling pathways, potentially impacting NSMA2 by altering the cellular signaling landscape, particularly in cell proliferation and survival. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor affecting the MAPK/ERK pathway. By inhibiting MEK, Trametinib can modulate cell growth and differentiation signals, potentially influencing NSMA2's activity indirectly through changes in gene expression and cellular signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor, impacting pathways related to cell growth and survival. By inhibiting EGFR, Gefitinib can modulate various cellular processes, potentially influencing NSMA2 by altering signaling pathways involved in cell proliferation and differentiation. | ||||||